GUIDEMARK HEALTH AND CYAN HEALTH ARE NOW LUMANITY
Guidemark Health and Cyan Health have today rebranded, changing their names to Lumanity. The two agencies were acquired by Lumanity in 2021.
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
U.S. FDA declines to approve Spero’s urinary tract infection drug
/in R&D, TherapeuticsThe U.S. Food and Drug Administration (FDA) declined to approve Spero Therapeutics Inc.’s oral antibiotic drug for the treatment of patients with complicated urinary tract infections, the company said on Monday.
U.S. Supreme Court sides with doctors challenging opioid convictions
/in TherapeuticsThe U.S. Supreme Court on Monday gave two doctors found guilty of misusing their licenses in the midst of the U.S. opioid epidemic to write thousands of prescriptions for addictive pain medications another chance to challenge their convictions.
Ipsen snags Epizyme and cancer portfolio for a cool $247 million
/in Business, R&D, Therapeutics“We expect that this acquisition and Ipsen’s commitment to invest in the oncology space will ensure our epigenetic pipeline continues to advance in a way we could not have done on our own to bring transformative cancer therapies to patients in need,” Bogle said in a statement,” company CEO David Loew said in a statement.
FDA Proposes New Guidance For Broader Consumer Access to Nonprescription Drugs
/in FDA/Regulatory, TherapeuticsThe proposed rule is intended to increase options for the development of safe and effective nonprescription drugs, according to the agency.
More gene therapy woes for Astellas as FDA presses pause on Pompe trial
/in R&D, TherapeuticsThe U.S. Food and Drug Administration has placed Astellas Pharma’s Phase I/II FORTIS trial on clinical hold after one of its study participants experienced a serious adverse event (SAE).
U.S. Supreme Court again nixes Bayer challenge to weedkiller suits
/in Business, TherapeuticsThe U.S. Supreme Court on Monday rejected another Bayer AG bid to dismiss litigation alleging that its Roundup weedkiller causes cancer as the German pharmaceutical and chemical giant tries to avoid potentially billions of dollars in damages.
White House prepares to fight states over abortion pill
/in FDA/Regulatory, TherapeuticsPresident Joe Biden’s administration indicated it will seek to prevent states from banning a pill used for medication abortion in light of the Supreme Court ruling overturning the landmark Roe v. Wade ruling, signaling a major new legal fight.
AstraZeneca gets EU backing for targeted breast cancer therapies
/in Business, TherapeuticsThe company stated that two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the European Union, in a boost to the company’s oncology portfolio.
WHO says monkeypox is not yet a health emergency
/in R&D, TherapeuticsMonkeypox is not yet a global health emergency, the World Health Organization (WHO) ruled on Saturday, although WHO Director-General Tedros Adhanom Ghebreyesus said he was deeply concerned about the outbreak.
